Hyseq Pharmaceuticals Appoints Two New Members to Its Board Of Directors
SUNNYVALE, Calif., June 17 /PRNewswire-FirstCall/ -- Hyseq Pharmaceuticals, Inc. (Nasdaq: HYSQ - News), today announced the appointment of Mary K. Pendergast, J.D., LL.M. and Richard B. Brewer to its board of directors.
Ms. Pendergast currently serves as executive vice president, government affairs at Elan Corporation, where she is involved in significant regulatory, strategic and government issues. Prior to joining Elan, Ms. Pendergast was the deputy commissioner and senior advisor to the Commissioner at the U.S. Food and Drug Administration (FDA) from 1990 to 1998. There she led the agency's efforts to revise its regulation of emerging scientific areas such as biotechnology, cellular and tissue-based therapies, xenotransplantation, genetic testing and acute care research. She also served as the FDA's "crisis manager," handling sensitive, critical or precedent-setting situations and provided leadership across the agency on high priority initiatives.
Ms. Pendergast also served as associate chief counsel for enforcement at the FDA from 1979 to 1990 and as attorney, Office of the General Counsel, Department of Health and Human Services from 1977 to 1979. She is on the board of directors for the Regulatory Affairs Professional Society and is vice-chair for the committee on food, drug and cosmetic law for the American Bar Association. Ms. Pendergast received her LL.M, J.D. and B.A. from Yale Law School, the University of Iowa College of Law and Northwestern University, respectively.
A biotechnology and pharmaceutical veteran, Mr. Brewer currently serves as president and chief executive officer of Scios Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. From 1996 to 1998, Mr. Brewer served as chief operating officer at Heartport, a cardiovascular device company, and held various positions at Genentech, Inc., from 1984 to 1995, including senior vice president for sales and marketing in the U.S., Europe and Canada.
Mr. Brewer served as a member of the American Heart Association (AHA) corporate roundtable from 1993 to 1994, the chairman of the AHA pharmaceutical roundtable from 1994 to 1995 and in 2001, was appointed as an advisory board member at the Kellogg Graduate School of Management, Center for Biotechnology at Northwestern University.
Mr. Brewer received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.S. in biology from Virginia Polytechnic Institute.
"We are very excited to welcome such experienced biotechnology executives to our board of directors and I look forward to working with them," said Dr. Ted W. Love, president and chief executive officer of Hyseq Pharmaceuticals. "We will be able to leverage Dick's experience in turning Scios into the success it is today, while utilizing Mary's extensive regulatory expertise to help us navigate the challenges of getting afimeprase through clinical trials and onto the market as fast as possible."
Upcoming Events
Hyseq will hold its annual shareholder's meeting on Tuesday August 6, 2002 at 11:00 a.m. (Pacific Time) at 675 Almanor Avenue, Sunnyvale, CA 94085.
About Hyseq
Hyseq Pharmaceuticals, Inc. is engaged in research and development of novel biopharmaceutical products from its collection of proprietary genes discovered using its high-throughput screening-by-hybridization platform. Hyseq's screening-by-hybridization platform provided a significant advantage in discovering novel, rarely-expressed genes, and assembly of one of the most important proprietary databases of full-length human gene sequences. Hyseq is expanding and accelerating its research activities to further elucidate the role of novel genes in its proprietary database. Hyseq's database includes genes which encode a number of therapeutically important classes of molecules including chemokines, growth factors, stem cell factors, interferons, integrins, proteases, hormones, receptors, and other potential protein therapeutics or drug targets.
Information about Hyseq Pharmaceuticals is available at www.hyseq.com or by phoning 408-524-8100.
Statements contained in this press release which are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Act of 1995. Forward-looking statements may be identified by words such as "believe," "expect," "anticipate," "should," "may," "estimate," "goals," and "potential," among others. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to unanticipated difficulties and delays relating to gene identification, drug discovery and clinical development processes; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and regulatory approval; and uncertainties relating to our ability to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and described in more detail in our periodic reports filed from time to time with the SEC, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2001. We disclaim any intent or obligation to update these forward-looking statements.
SOURCE: Hyseq Pharmaceuticals, Inc. |
